Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer
Initial findings of the phase III KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy—first presented at ASCO 2021—have led to the subsequent FDA approval of this combination for the first-line treatment ...
Dec 15, 2021
0
41